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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientiﬁc opinion on the safety of Ecklonia cava
phlorotannins (marketed as SeaPolynolTM) as a novel food submitted pursuant to Regulation (EC)
No 258/97. The novel food is a phlorotannin-rich alcohol extract of Ecklonia cava, which is an edible
marine brown alga species. The information provided on the composition, the speciﬁcations, the
production process and the batch-to-batch variability of the novel food is sufﬁcient and does not raise
safety concerns. The intention is to market the novel food as a food supplement for healthy individuals
over the age of 12 years. A subchronic repeated dose oral toxicity study in rodents tested the novel
food at daily doses of 0, 375, 750 and 1,500 mg/kg body weight (bw). The Panel considers the mid-
dose as the no-observed-adverse-effect-level (NOAEL) of the study. Taking into account this NOAEL of
750 mg/kg bw per day and by applying an uncertainty factor of 200, the Panel considers an intake
level of 3.75 mg/kg bw per day as safe. The Panel concludes that the novel food, Ecklonia cava
phlorotannins, is safe for the use in food supplements at a maximum daily intake level of 163 mg/day
for adolescents from 12 to 14 years of age, 230 mg/day for adolescents above 14 years of age and
263 mg/day for adults.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientiﬁc opinion on the safety of Ecklonia cava
phlorotannins as a novel food (NF) submitted pursuant to Regulation (EC) No 258/97. The assessment
follows the methodology set in Commission Recommendation 97/618/EC. The assessment is based on
the data supplied in the original application, the initial assessment by the competent authority of
Ireland, the concerns and objections of a scientiﬁc nature raised by the other Member States and the
responses of the applicant.
The NF which is the subject of the application is an alcohol extract of Ecklonia cava, which is an
edible marine brown alga species with a long tradition of food use in a number of Asian countries. The
extract is rich in phlorotannins (90  5%) and it is marketed under the trade name of SeaPolynolTM.
Phlorotannins are polyphenolic compounds found as secondary metabolites in certain brown algae
species.
The information provided on the composition, the speciﬁcations, the production process and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
The intention is to market the NF as a food supplement, with a proposed maximum daily intake of
360 mg. The target population for the NF is healthy individuals over the age of 12 years, with no
other restrictions of use.
Based on the genotoxicity tests provided, the Panel notes that there is no evidence of genotoxicity
for the NF.
The risk of allergic reactions to the NF is low.
A subchronic repeated dose oral toxicity study in rodents was provided, which tested the NF at
daily doses of 0, 375, 750 and 1,500 mg/kg body weight (bw). The Panel considers the mid-dose, i.e.
750 mg/kg bw per day, as the no-observed-adverse-effect-level (NOAEL) of the study.
Taking into account the NOAEL of 750 mg/kg bw per day and by applying an uncertainty factor of
200 (composed of 100 to account for inter- and intraspecies variability, plus a factor of 2 to extrapolate
from subchronic to chronic exposure), the Panel considers an intake level of 3.75 mg/kg bw per day as
safe.
This level corresponds to 163 mg/day for adolescents from 12 to 14 years of age (mean bw of
43.4 kg), 230 mg/day for adolescents above 14 years of age (mean bw of 61.3 kg) and 263 mg/day
for adults (default bw of 70 kg).
The Panel concludes that the NF, Ecklonia cava phlorotannins, is safe for the use in food
supplements at a maximum daily intake level of 163 mg/day for adolescents from 12 to 14 years of
age, 230 mg/day for adolescents above 14 years of age and 263 mg/day for adults.
The Panel notes that iodine intake from the NF may be of concern for people at risk of thyroid
disease. The Panel also notes that intake of other food supplements containing iodine in addition to
the NF might lead to iodine intakes above the upper level (UL).
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 14 May 2015, the company Botamedi Inc., Korea, submitted a request in accordance with
Article 4 of the Novel Food Regulation (EC) No 258/971 to place on the market Ecklonia cava
phlorotannins as a novel food (NF).
On 4 April 2016, the competent authority of Ireland forwarded to the Commission its initial
assessment report, which came to the conclusion that an additional assessment is required in
accordance with Article 6.3 of the Novel Food Regulation (EC) No 258/97.
On 10 May 2016, the Commission forwarded the initial assessment report to the other Member
States (MS). The MS agreed with the initial assessment report made by the Food Safety Authority of
Ireland and some of the MS included additional comments.
The concerns of a scientiﬁc nature raised by the MS can be summarised as follows:
• Regarding the speciﬁcations of the NF, there is some unclarity, in particular since a method of
analysis (i.e. Folin–Ciocalteu method, using a polyphenol-dihydrate standard) was used for
quantiﬁcation of the phlorotannin content, which, according to the commenting MS, is prone to
yield erroneous values.
• Concerns were raised on a signiﬁcant proportion of not fully characterised phlorotannins
present in the NF. Moreover, data on the absorption, distribution, metabolism and excretion
(ADME) of phlorotannins in the human body were considered limited.
• The phloroglucinol in the NF might be broken down and release trihydroxybenzene monomers
which may be of toxicological concern.
• The level of arsenic in the NF may pose a safety concern. The additional (i.e. in addition to the
normal background diet) intake of arsenic via the NF may be signiﬁcant and therefore may
need to be lowered in the NF, in particular considering that the NF (in the form of a food
supplement) might be consumed for extended periods of time.
• Given the high iodine content of the NF, such content should be indicated on the label of the
NF in order to warn the consumer not to use the NF together with other food supplements
and/or drugs high in iodine.
• The description of the extraction process was considered inadequate.
• Concerns were raised on the selection of the no-observed-adverse-effect-level (NOAEL) (i.e.
mid-dose), since statistically insigniﬁcant but dose-related effects on body weight were
observed also in the lower- and mid-dose groups.
• More information was required about the mode of action of the NF.
• One MS suggested considering a potential effect of the NF on glucose metabolism of diabetic
individuals and people on anticoagulant therapy.
• One MS mentioned putative sleep-inducing effects of phlorotannins, claimed to have
characteristics of GABAA-BZD receptor ligands (Cho et al., 2012).
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20022, the European Food Safety
Authority (EFSA) is asked to carry out the additional assessment for Ecklonia cava phlorotannins
(marketed as SeaPolynolTM) as a NF in the context of Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of a scientiﬁc
nature in the comments raised by the other MS.
2. Data and methodologies
2.1. Data
The assessment of the safety of the novel food (NF) is based on data supplied in the original
application, the initial assessment by the competent authority of Ireland, the concerns and objections
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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of a scientiﬁc nature of the other MS and the responses of the applicant following requests for
additional information.
In accordance with Commission Recommendation 97/618/EC,3 the NF, Ecklonia cava phlorotannins,
is allocated to Class 2.2, i.e. a complex NF from non-GM source where the source has no history of
food use in the Community. The data requirements for a NF of this class are the structured schemes I,
II, III, IX, XI, XII and XIII, as stipulated by Commission Recommendation 97/618/EC. In the current
scientiﬁc opinion, these structured schemes are listed in Sections 3.1–3.9. The intention is to market
the NF in the form of food supplements. This assessment concerns only risks that might be associated
with consumption of the NF under the proposed conditions of use, and is not an assessment of the
efﬁcacy of Ecklonia cava phlorotannins (SeaPolynolTM) with regard to any claimed beneﬁt.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29
July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to support
applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
3.1. Speciﬁcation of the NF
The NF which is the subject of the application is an alcohol extract of E. cava, which is an edible
marine brown alga species. The extract is rich in phlorotannins (90  5%) and it is marketed under
the trade name of SeaPolynolTM.
Phlorotannins are polyphenolic compounds found as secondary metabolites in certain brown algae
species (such as E. cava). They are structurally different from land-based plant polyphenols (e.g.
resveratrol, quercetin, epigallocatechin gallate) with the polymers/oligomers made of phloroglucinol
(1,3,5-trihydroxybenzene).
The speciﬁcations of the NF are indicated in Table 1. They include the phlorotannin content of the
NF as well as other chemical and physical parameters and speciﬁcations for contaminants such as
heavy metals, microbiological speciﬁcations and impurities.
Table 1: Speciﬁcations of the NF
Parameter Unit Speciﬁcation Method
Phlorotannin PGEQ%(a) 90.0  5.0 Folin–Ciocalteu’s method
Dieckol % 6.6–9.9 HPLC
Area Ratio BE cluster to Dieckol(b) – 1.0–1.6 HPLC
Antioxidant activity % > 85 DPPH (reduction%, c = 0.1 mg/mL)
Moisture content % < 5 Moisture analyser
Ash % < 5 Direct ashing method
Insoluble substances(c) – negative Dissolve and ﬁltration method
Substances not originating from
E. cava(d)
– negative Dissolve and ﬁltration method
Visual inspection
Appearance – brown powder Visual inspection
Unpleasant odour or taste – negative Sensory test
Viable cell count CFU/g < 3,000 3M Petriﬁlm method: PP-6406
Staphylococcus aureus CFU/g negative 3M Petriﬁlm method: PP-6424
Moulds and yeasts CFU/g < 300 3M Petriﬁlm method: PP-6417
Salmonella ssp. CFU/25 g negative 3M Petriﬁlm method: PP-6539
Coliforms CFU/g negative Using BGLB media
3 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council. OJ L 253, 16.9.1997, p. 1–36.
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In order to conﬁrm that the manufacturing process is reproducible and adequate to produce on a
commercial scale a product that is within the speciﬁcations as set above, the applicant provided batch-
to-batch analyses (Table 2) for six batches of the NF.
Parameter Unit Speciﬁcation Method
Lead (Pb) mg/kg < 3 ICP-MS
Mercury (Hg) mg/kg < 0.1 ICP-MS
Cadmium (Cd) mg/kg < 3 ICP-MS
Arsenic (As) mg/kg < 25 ICP-MS
Iodine (I2) mg/kg 150.0–650.0 AOAC method: 932.21
Sieving size mesh > 60 Standard sieving method
HPLC: high-performance liquid chromatography; DPPH: 2,2-diphenyl-1-picrylhydrazyl; CFU: colony forming unit; BGLB: brilliant
green lactose bile; ICP-MS: inductively coupled plasma mass spectrometry.
(a): Phloroglucinol equivalent using anhydrous phloroglucinol standard.
(b): BE cluster – cluster in chromatogram of 3 peaks consisting of 4 compounds:
2-O-(2,4,5-trihydroxyphenyl)-6,6′-bieckol, 6,6′-bieckol and 8,8′-bieckol + 7-phloroeckol.
(c): Originating from Ecklonia cava (e.g. non-soluble cellulosic residues).
(d): Any ‘foreign’ substance introduced erroneously during the manufacturing process.
Table 2: Batch-to-batch analysis of the NF
Parameter Speciﬁcation
Batch results of six commercial lots
20121124 20130425 20130827 20140408 20140410 20140728
Phlorotannin 90  5%(a) 90.1 88.1 89.9 88.3 90.2 90.2
Antioxidant
activity
> 85% 91.4 90.8 90.4 88.5 89.1 88.1
Moisture
content
< 5% 1.8 3.2 4.7 3.2 2.5 2.6
Ash < 5% 3.1 3.1 3.8 3.2 3.6 3.2
Insoluble
substances(b)
Negative Negative Negative Negative Negative Negative Negative
‘Foreign’
substances(c)
Negative Negative Negative Negative Negative Negative Negative
Appearance Brown powder Conforms Conforms Conforms Conforms Conforms Conforms
Unpleasant
odour or
taste
Negative Negative Negative Negative Negative Negative Negative
Viable cell
count
< 3,000 CFU/g 0 0 0 0 0 0
Staphylococcus
aureus
Negative Negative Negative Negative Negative Negative Negative
Moulds and
yeasts
< 300 CFU/g 0 0 0 0 0 0
Coliforms(d) Negative Negative Negative Negative Negative Negative Negative
Lead < 3 mg/kg 1.32 1.82 2.81 1.53 1.52 1.67
Mercury < 0.1 mg/kg n.d. n.d. n.d. n.d. n.d. n.d.
Cadmium < 3 mg/kg 0.08 0.12 0.156 0.13 0.08 0.14
Arsenic < 25 mg/kg 21.30 16.56 21.69 21.49 23.40 19.81
Iodine < 650 mg/kg 168.4 174.9 281.6 218.9 240.2 226.9
Sieving size > 60 mesh > 60 > 60 > 60 > 60 > 60 > 60
CFU: colony forming unit; n.d.: not detected.
(a): Phloroglucinol equivalent using anhydrous phloroglucinol standard (PGEQ).
(b): Originating from Ecklonia cava (e.g. non-soluble cellulosic residues).
(c): Any substance not originating from Ecklonia cava introduced erroneously during the manufacturing process.
(d): Coliform analysis covers Escherichia coli. Since no coliforms are present, the applicant considered that a speciﬁc method to
distinguish E. coli from other coliforms is not necessary.
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Proximate analysis showed that the sum of crude protein, crude fat, ash and moisture account
for an average of 9.6 wt% of the NF. The amount of crude protein in the NF is approximately 2.2
wt% measured by the semimicro Kjeldahl method with a limit of detection (LOD) of ≥ 0.2 mg
nitrogen (ofﬁcial method of the Korean Food Codex). The amount of phlorotannins in the NF is
90.0  5.0 wt% as measured by a spectrophotometric Folin–Ciocalteu’s assay using anhydrous
phloroglucinol-dihydrate as the standard compound. The applicant also provided both HPLC- and
1H-NMR-data conﬁrming the presence of phlorotannins. The phlorotannins detectable with HPLC
include dieckol, 8,8′-bieckol and 7-phloroeckol, 2-O-(2,4,5-trihydroxyphenyl)-6,6′-bieckol, 6,6′-bieckol,
phlorofucofuroeckol-A, eckol, 2-phloroeckol, phlorotannin 974-A and 974-B, and fucofuroeckol with
approximately 14.4 wt% with unknown structure. As not all phlorotannins are detectable by HPLC,
the total unidentiﬁed phlorotannins amount to approximately 64 wt%. According to the applicant,
the unidentiﬁed structures are considered to be open-chain polymers of phloroglucinol.
The level of inorganic arsenic in the NF according to three batch analyses is < 0.5 mg/kg.
Considering the highest total arsenic amount of 23.40 mg/kg measured in the batch analyses, a daily
dose of 360 mg of NF would contribute to 8.4 lg to the daily intake. This represents an additional
13.2% exposure to total dietary arsenic of < 64 lg per day estimated in the 2006 UK Total Diet Study
(Rose et al., 2010).
The absence of residual ethanol was conﬁrmed by the gas chromatographic method.
Analysis of six product batches for the presence of 245 pesticide residues, seven PCB congeners,
and aﬂatoxins B1, B2, G1 and G2 were provided. Dioxins were detected only in one batch at 0.382 pg
TEQ/g (with contribution to TWI 0.01%). Traces of two pesticides, azinphos-methyl (0.028 mg/kg in
one sample) and phenthoate (0.162–0.442 mg/kg) were detected at low levels (to which the applicant
has responded by deciding to change the harvest location to ensure the absence of pesticide residues).
The Panel notes that there is no indication for the production of toxins by E. cava or any other
member of the order of the Laminariales.
The Panel considers that the information provided on the composition, the speciﬁcations and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
3.1.1. Stability of the NF
Upon EFSA0s request, the applicant provided data from a preliminary stability study showing that
the phlorotannin content and the dieckol content of three commercial lots (packed in aluminium-
polyethylene bags) of the NF were 99–100% and 97–100%, respectively, when stored at 25°C (RH
65%), 35°C (RH 75%), and 40°C (RH 75%) for 12 months. The phlorotannin content was measured
by the Folin-Ciocalteu’s method by using phloroglucinol-dihydrate as the standard compound. Dieckol
was measured by HPLC (7.5–8 wt%). A second stability study on ﬁve commercial lots indicated that
the NF is stable for 36 months at room temperature (25°C, RH 65%) as measured by the phlorotannin
and dieckol contents.
The Panel considers that the data provided sufﬁcient information with respect to the stability of the
NF.
3.2. Effect of the production process applied to the NF
The manufacturing process of the NF is in accordance with Good manufacturing practice (GMP)
standards and it takes into account the principles of Hazard Analysis and Critical Control Points
(HACCP). The manufacturer is holder of an ISO 22000:2005 certiﬁcate.
Production begins with fresh, semidried Ecklonia cava seaweed, which is dried, crushed and
subjected to alcohol (i.e. food-grade ethanol) extraction, puriﬁcation, ﬁltration and concentration steps.
E. cava is abundant in southern Japan and South Korea, and the location of the seaweed source has
been indicated as Jeju Island in South Korea. Each seaweed lot is visually inspected upon arrival for
processing and undergoes quality analysis. A ﬂow chart and detailed information on the manufacturing
process have been provided.
The Panel considers that the production process is sufﬁciently described and does not raise
concerns about the safety of the NF.
3.3. History of the organism used as a source of the NF
Ecklonia cava (Class: Phaeophyceae, Order: Laminariales, Family: Lessoniaceae) is a brown alga
abundant in the seas (coasts) of central and southern Japan and South Korea. The use of brown algae
Safety of Ecklonia cava phlorotannins
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as a food can be traced back to the fourth century in Japan and the sixth century in China (McHugh,
2003). E cava is consumed (in its natural form) as salad and in soups, but also in powder-form for the
seasoning and colouring of, for instance, miso soup, rice cakes, candies and kimchi (traditional
fermented Korean side dish). Upon EFSA’s request to provide information on the amount of
consumption of E. cava, the applicant argued that consumption data on speciﬁc species of seaweed
are difﬁcult to obtain. However, production data on Laminariales, which also includes E. cava, shows
that 86,000–110,000 tonnes were produced yearly (2011–2015) in Japan. Including import of 48,000
tonnes (2013), it has been calculated that the amount of seaweed consumed daily per capita in Japan
is 2.6 g (dry weight (dw)). For Korea, the amount of seaweed consumption per day and per capita is
5.2 g (dw).
The applicant also presented data on the use of E. cava as a source of alginates, which are used
for various applications including food.
Phaeophyceae, which include E. cava, are a source for alginates authorised in the European Union
(EU) as a food additive (E 400).
3.4. Anticipated intake/extent of use of the NF
The applicant intends to use the NF for inclusion in food supplements. The proposed maximum
intake of the NF is 360 mg/day.
The target population for the NF is healthy individuals over the age of 12 years, with no other
restrictions of use.
3.5. Information from previous human exposure to the NF or its source
The applicant has provided sales data (conﬁdential) for food supplements and beverages containing
the NF.
Food supplements containing Ecklonia cava phlorotannins have been sold in Japan and Korea since
2004. Since 2007 (Korea) and 2010 (Japan) ‘high-dose’ food supplements have been marketed, which
provide 200–1200 mg Ecklonia cava phlorotannins per day.
In the USA, food supplements with Ecklonia cava phlorotannins have been sold since 2006,
providing on average 100 mg of Ecklonia cava phlorotannins per day. In 2008, the Ecklonia cava
extract was notiﬁed to the FDA as a new dietary ingredient, with a proposed daily dose of about
47 mg Ecklonia cava phlorotannins per day.
No adverse effects have been reported.
3.6. Nutritional information on the NF
Minerals are present in the NF in relatively high concentrations including sodium (4,400  800 mg/kg),
calcium (4,800  400 mg/kg), magnesium (1,300  100 mg/kg), potassium (700  200 mg/kg) and
iodine (220  40 mg/kg). In the upper range of iodine content as indicated in the speciﬁcations (up to
650 mg/kg), the proposed intake of the NF (360 mg) would lead to an iodine intake of 234 lg. In
addition to iodine intake from food (excluding other food supplements), the total intake might exceed
the reference value for iodine but will not exceed the upper level (UL; 450 lg for adolescents from 11
to 14 years, 500 lg for adolescents from 15 to 17 years and 600 lg for adults (SCF, 2002)). Taking
into account the composition of the NF and the intended use level, the Panel considers that the
consumption of the NF is not nutritionally disadvantageous.
3.7. Microbiological information on the NF
Microbiological speciﬁcations for the NF are presented in Table 1 (Section 3.1). The applicant
provided analytical results for six batches of the NF, which were compliant with the microbiological
speciﬁcations (Table 2, Section 3.1). Results for three additional batches were provided, which had
been tested for the presence of Salmonella spp. Overall, the results show that yeast and moulds,
coliforms (including Escherichia coli), Staphylococcus aureus and Salmonella are below the detection
limit.
The Panel considers that the microbiological information provided for the NF does not raise safety
concerns.
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3.8. Toxicological information on the NF
The NF (SeaPolynolTM) used in the following good laboratory practice (GLP) studies was
manufactured according to the same raw material and extraction process and contains equivalent
concentrations of phlorotannins (92  7%, using the dihydrous phloroglucinol standard).
All studies were performed according to Korean regulations for Good Laboratory Practice and
according to Korean Test Guidelines for Safety Evaluation of Drugs. If not mentioned otherwise, the
design of the studies is comparable to corresponding OECD guidelines.
3.8.1. Absorption, distribution, metabolism and excretion
In a study on toxicokinetics (MPI Research Inc., 2013) provided by the applicant, groups of four
male Sprague–Dawley [Crl:CD®(SD)] rats each received 10 mg/kg body weight (bw) of the NF (Lot
47-809) i.v., and 10, 100 and 1,000 mg NF/kg bw orally via gavage. Blood samples were collected
pre-dose and at 15 and 30 min and 1, 2, 4, 6, 8, 12, 24 and 36 h post-dose and levels for the
phlorotannins constituents dieckol, 8,80-bieckol and phlorofucofuroeckol-A (PFF-A) in plasma were
determined.
PFF-A was only detected after i.v. administration of 10 mg/kg bw and up to 1 h after oral
administration of 1,000 mg/kg in a single rat and was much lower than for the other two components.
While readily detectable after intravenous administration of 10 mg/kg bw, after gavage of 10 mg/kg
bw NF bieckol and dieckol could also not be detected. In contrast to PFF-A, they could be detected
after oral application of 100 and 1,000 mg/kg bw. For both, a more than proportional increase (factor
84 and 49 instead of 10) of the AUC from 100 to 1,000 mg/kg bw with dose is remarkable. Half-life
periods for bieckol and dieckol ranged from 2.95 to 6.63 h and from 2.76 to 6.61 h for the two dose
levels, respectively. Bioavailability following oral gavage administration was approximately 0.069–0.5%
for 8,8′ bieckol and 0.06–0.23% for dieckol.
Studies with polyphenols from other algae indicate glucuronidation and sulfation in the intestine
(Corona et al., 2016). Furthermore, after passing the small intestine, the polyphenols are metabolised
by the colonic microbiota into a wide range of low-molecular-weight phenolic acids that are absorbed
and appear in the circulation after 6–24 h.
3.8.2. Genotoxicity
The applicant provided a bacterial reverse mutation test, an in vitro chromosome aberration test
and an in vivo micronucleus test.
In the in vitro bacterial reverse mutation test (Biotoxtech Co. Ltd., 2006a), the NF was tested in the
Salmonella Typhimurium strains (TA98, TA100, TA1535 and TA1537) and E. coli (WP2uvrA(pKM101))
strains without and with metabolic activation system (S9 mix). The number of revertant colonies was
not increased with and without metabolic activation up to 5,000 lg/plate. No cytotoxicity was
observed.
In the in vitro chromosome aberration test (Biotoxtech Co. Ltd., 2006b) in Chinese hamster lung
cells (CHL/IU), the NF was tested with concentrations up to 290 lg/mL, which was the IC50 (inhibition
concentration 50%) in a pre-test. The number of cells with structural chromosome aberrations was not
increased by the NF as compared with the negative control group, in the presence or absence of
metabolic activation system in both the short time and continuous treatment. In the positive control
group, the number of cells with structural chromosome aberration was signiﬁcantly increased as
compared with the negative control group.
In a pre-test for an in vivo micronucleus test (Biotoxtech Co. Ltd., 2006c), 2,000 mg/kg bw NF
(Lot No. LC-SP-20060626; tannin content ≥ 95%) was administered once by gavage to three male
Crlj:CD1(ICR) mice per group and the bone marrow (2,000 erythrocytes) was checked for the
frequency of micronuclei, after 24, 48 and 72 h. There was no increase in the frequency of micronuclei
in any of the time points. In the main test, ﬁve male mice per group received via gavage 500, 1,000 and
2,000 mg/kg body weight. After 24 h, the frequency of micronucleus induction was determined per
2,000 erythrocytes. There was no signiﬁcant difference in the frequency of micronucleated polychromatic
erythrocytes (MNPCE) for all treatment groups compared with that of the negative control. The
polychromatic erythrocytes (PCE)/(PCE + normochromatic erythrocytes (NCE)) ratio was not signiﬁcantly
different between treatment groups and control groups. In conclusion, the test substance (i.e. the NF)
did not induce micronucleus formation in bone marrow cells in mice. The Panel notes that even though
the group of parent compounds (i.e. phlorotannins) in the NF are unlikely to reach the bone marrow, the
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metabolically produced phenolic compounds therefrom can be expected to be absorbed and reach the
bone marrow. This assumption is further corroborated by systemic effects in the subchronic toxicity study
(Section 3.8.5), which suggests systemic availability of the NF and/or its metabolites.
The Panel notes that there is no evidence of genotoxicity for the NF.
3.8.3. Acute toxicity studies
In an acute toxicity study (Biotoxtech Co. Ltd., 2007a) provided by the applicant, 10 male and 10
female Sprague–Dawley (Crl:CD(SD)) rats were administered once orally by gavage 2,000 mg NF/kg bw.
Findings in the 14 days observation period were soft stools, diarrhoea, mucous stools, compound-coloured
faeces and soiled perineal region from the day of administration until day 2. No mortalities occurred.
In a second study (Biotoxtech Co. Ltd., 2007b), two male and two female Beagle dogs were
administered the NF in capsules at intervals of 4 days, i.e. day 0: 100 mg/kg bw, day 4: 300 mg/kg
bw and day 8: 1,000 mg/kg bw. Two male and two female dogs served as controls. After the last
application, there was a 2-week observation period. Compound-coloured stools were observed in all
males and females treated with 300 and 1,000 mg/kg bw. Vomiting was observed in one male and
one female dog receiving 1,000 mg/kg bw. No mortalities occurred.
3.8.4. Subacute toxicity studies
In a dose-range ﬁnding study (Biotoxtech Co. Ltd., 2010a) for a subchronic toxicity study, ﬁve male
and ﬁve female Sprague–Dawley (Crl:CD(SD)) rats per group were administered the NF by gavage at
doses of 0, 500, 1,000 and 2,000 mg/kg bw once daily in water for 4 weeks. Compound-coloured
stools were evident in all males and females in the dosing groups from day 1 during the dosing period.
Salivation after dosing was evident sporadically in one female at 1,000 mg/kg bw and in two males
and two females at 2,000 mg/kg bw from days 5 to 17 during the dosing period. In clinical chemical
investigations at 2,000 mg/kg bw per day, statistically signiﬁcant increases in alanine aminotransferase
(ALT), and decreases in total protein, triglycerides and glucose were detected in male rats. In addition,
absolute and relative liver weights and absolute kidney weights were statistically signiﬁcantly increased
in males at 2,000 mg/kg bw per day. In female rats, relative heart weights were decreased statistically
signiﬁcantly at 1,000 and 2,000 mg/kg bw per day. There were no statistically signiﬁcant differences
between the study groups concerning body weight. Histopathologically, atrophy of periportal
hepatocytes in the liver was detected in male rats at 2,000 mg/kg bw per day.
In another study (Yeo et al., 2012), which was an efﬁcacy study, mice (7 weeks of age, 10 mice per
group) were fed a diet containing an increased amount of fat, i.e. 20%, as compared to 5–10% in usual
rodent diets. After 1 week, the animals received in addition each day 0, 1.25, 2.5 and 5 mg/mouse of
the NF orally for further 3 weeks. These dosages correspond to 27, 54 and 135 mg NF/kg bw per day. An
additional group was fed a diet without fat, and there were also groups receiving various amounts of
dieckol, one of the major phlorotannins in the NF. At the end of the study, there was a dose-related lower
body weight of about 12–16% in the animals receiving the NF compared to control. Triglycerides, total
cholesterol and low-density lipoprotein (LDL) cholesterol were decreased in all dose groups. Liver
enzymes (glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT)), blood urea
nitrogen (BUN) and creatinine values in serum were not affected. No data on food consumption were
provided.
3.8.5. Subchronic toxicity studies
A subchronic toxicity study (Biotoxtech Co. Ltd., 2010b) in rodents was provided by the applicant.
In this study, 10 male and 10 female Sprague–Dawley (Crl:CD(SD)) rats were administered by gavage
for 13 weeks the NF once daily in water at doses of 0, 375, 750 and 1,500 mg/kg bw. In order to
assess the reversibility of potential effects, ﬁve additional animals per sex for the control and the high-
dose group were investigated after a 4-week recovery period.
Compound-coloured stools occurred at all dose levels. These compound-coloured stools were likely
caused by excretion of the test substance and were thus not considered to be of toxicological
signiﬁcance.
At a dose of 750 mg/kg bw per day and above, BUN was statistically signiﬁcantly decreased in males,
glucose was statistically signiﬁcantly decreased in females and neutrophil counts were signiﬁcantly
increased in females, compared to controls. In addition, sporadic salivation occurred in females.
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At a dose of 1,500 mg/kg bw per day, incidence of salivation in females increased and it occurred also
in male rats. Salivation was mainly observed after gavage, but to some degree also before. It was
considered by the authors of the study to be a temporary sign caused by the test substance, since it was
no longer evident in the afternoon. The number of animals with salivation increased with study duration.
At 1,500 mg/kg bw per day, males and females receiving the NF had a lower body weight (11.7%
and 8.7%, respectively) at the end of the study compared to control animals even though differences
were not statistically signiﬁcant. This effect was dose related, appearing to a minor degree also at the
lower dose levels. Effects on body weight were even more pronounced in the recovery group in both
sexes. Food consumption, however, was not decreased. Blood chemistry analyses showed signiﬁcant
increases of phosphorus and ALT concentrations in males, a signiﬁcant decrease of triglycerides in
males and a signiﬁcant decrease of glucose in females receiving 1,500 mg/kg bw per day, compared to
controls. In addition, prothrombin time was statistically signiﬁcantly increased in males compared to
controls. These changes were not evident during the recovery. There were no compound related
ﬁndings in histopathological investigations including the liver.
The Panel considers that the salivation observed after administration of the NF may be due to bad
taste/astringent properties which may not be tolerated even with minor amounts of test substance
during gavage. It is considered to be rather concentration than dose-dependent.
The Panel notes that at a dose of 1,500 mg/kg bw per day, in addition to the lower body weight
(which, although not statistically signiﬁcant, was taken by the authors of the study as the lowest-
observed-adverse-effect-level (LOAEL)), ALT and prothrombin time were increased, while BUN was
decreased as compared to controls. These ﬁndings may indicate liver toxicity, which has been
conﬁrmed histopathologically at higher dose levels in the 28-day study.
The Panel considers that the statistically signiﬁcant ﬁndings in the mid-dose group are small, only
found in one gender, are within normal ranges (neutrophils), might be related to metabolic effects
(BUN and glucose) owing to a lower body weight gain, and are, thus, not considered adverse.
The Panel, therefore, considers the mid-dose, i.e. 750 mg/kg bw per day, as the NOAEL of the
study.
3.8.6. Human studies
The applicant provided four published human studies (Oh et al., 2010; Lee et al., 2012; Shin et al.,
2012; Choi et al., 2015) which were performed with Ecklonia cava phlorotannins. For the publication
by Choi et al. (2015), the applicant provided the unpublished study report by Park and Choi (2012).
A double-blind, placebo-controlled, crossover study was conducted by Oh et al. (2010) in order to
assess an acute effect of (pre-exercise) Ecklonia cava phlorotannin supplementation on endurance
performance in 20 male college students during highly intense exercise. The Panel considers that no
conclusions can be drawn from this acute efﬁcacy study for the safety assessment of the NF.
Lee et al. (2012) conducted an uncontrolled open-label, single-arm study to assess the effect of
Ecklonia cava phlorotannins in 52 individuals with hypercholesterolaemia (fasting total cholesterol
concentration > 240 mg/dL or LDL cholesterol concentration > 130 mg/dL). The prevalence of
hypertension and diabetes mellitus in the sample was 23.4% and 8.7%, respectively. All subjects
consumed daily 400 mg of Ecklonia cava phlorotannins (Lot No. SP-20081216; phlorotannin content
98.5% (PGDEQ)). Haematological, clinical chemical parameters as well as urinalysis did not indicate
adverse effects. One case (2.2%) each of nausea, dyspepsia, diarrhoea and alopecia was reported.
Shin et al. (2012) conducted a 12-week randomised, double-blind, three-arm parallel trial in
107 overweight (BMI: 24–29 kg/m2) Korean men and women to assess the effects of Ecklonia cava
phlorotannins on anthropometric and blood lipid parameters. Subjects were randomly distributed to
one of the following three study groups: (i) placebo, (ii) 72 mg/day Ecklonia cava phlorotannins or (iii)
144 mg/day Ecklonia cava phlorotannins (Lot No. SP-20080510; phlorotannin content 98.5%
(PGDEQ)). The study enrolled 107 subjects (69 women and 38 men) between 19 and 55 years of age,
of which 97 subjects completed the trial. No power calculations were provided. Differences over time
and between treatments were determined using two-factor analysis of variance (ANOVA) with
repeated measures. There were no noticeable signs of adverse events related to ingestion of the
supplement, and a panel of routine serum clinical chemistries and haematological parameters, which
included WBC counts, remained within normal ranges during the intervention period.
A randomised, double-blind, placebo-controlled trial (Choi et al., 2015; unpublished study report
by Park and Choi, 2012) with the NF was conducted in subjects with hyperlipidaemia (total cholesterol
> 200 mg/dL or LDL cholesterol > 110 mg/dL). A total of 80 men and women between 19 and 80 years
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were enrolled. Study participants ingested 400 mg/day of the NF (Lot No. SP-20101012; phlorotannin
content 98.2% (PGDEQ)) or a placebo for 12 weeks. Two subjects (one from each group) discontinued
the study because they had withdrawn their consent. Two participants in the placebo group were
excluded from the analyses due to lack of compliance. Thirteen participants (6 and 7 subjects from the
NF and placebo group, respectively) were excluded from the analyses because of their family history in
hyperlipidaemia, resulting in 63 subjects who were included for the primary and secondary endpoint
analysis. For the safety assessment, all the enrolled subjects (n = 80) were considered. Sample size
power calculations were based on total cholesterol levels in the test and placebo group after 12 weeks
of 10.1 and 5.6 mg/dL, respectively, with a standard deviation (SD) of 7.2 mg/dL in both groups. It was
calculated that for a power of 80% with a 2-tailed alpha of 0.05, a total of eighty subjects were
needed, allowing for a 20% dropout rate. Differences between groups were analysed using a linear
mixed-effects model. No differences were seen between the study groups regarding the concentration
of liver enzymes (ALT and aspartate transaminase (AST)). There were 10 cases (in 8 subjects, 4 per
study group) of mild adverse events that were not considered related to consumption of the test
product. Statistically signiﬁcant differences were seen between the groups for white blood cell counts
and high-sensitive C-reactive protein (hs-CRP). However, the observed differences were small, remained
within normal ranges and might have resulted from apparent differences between study groups at
baseline. Therefore, the Panel considers these ﬁndings not to be of clinical relevance.
3.8.7. Other studies
One MS expressed concerns as to claimed sleep-inducing effects of phlorotannins in E. cava as
investigated in the animal study by Cho et al. (2012). In this study, an ethanol extract of E. cava
administered (p.o.) at doses up to 1,000 mg/kg bw to mice treated with pentobarbital (i.p.) increased
sleep duration and decreased sleep latency when compared to control. Administration of the extract
alone, i.e. without pentobarbital, did not induce sleep. The Panel notes that in this study the
administration of an ethanol extract of E. cava at 1,000 mg/kg bw did not induce sleep in mice. The
Panel also notes that in the 90-day oral toxicity study (Section 3.8.5), which was performed with doses
up to 1,500 mg/kg bw per day, no evident behavioural changes in the studied animals were reported.
3.9. Allergenicity
The NF contains on average 2.2% protein. The applicant performed a literature search in databases
such as AllergenOnline, Pubmed, Scopus and Web of Science, in order to retrieve any information on a
positive relationship between E. cava and allergenicity. The applicant also considered history of
traditional use and information from current commercial consumption of the NF and clinical trials
performed with Ecklonia cava phlorotannins. The applicant did not identify any evidence of allergenicity
to E. cava. Furthermore, the applicant states that the US and Asian distributors of Ecklonia cava
phlorotannin-containing food supplements (i.e. SeaPolynolTM) have adverse event reporting procedures
in place and that to date allergic reactions to the NF have not been reported.
The Panel considers that the risk of allergic reactions to the NF is low.
4. Discussion
The NF which is the subject of the application is a phlorotannin-rich (90  5%) alcohol extract of
the edible brown alga E. cava.
The information provided on the composition, the speciﬁcations, the production process and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
Brown algae, including E. cava, have a long tradition of food use in a number of Asian countries.
Food supplements containing Ecklonia cava phlorotannins are being sold in Japan, Korea and the USA.
The intention is to market the NF as a food supplement, with a proposed maximum daily intake of
360 mg. The target population for the NF is healthy individuals over the age of 12 years, with no
other restrictions of use.
The Panel notes that there is no evidence of genotoxicity for the NF.
A subchronic toxicity study was provided, which tested the NF in rodents at daily dosages of 0,
375, 750 and 1,500 mg/kg bw. The Panel considers the mid-dose, i.e. 750 mg/kg bw per day, as the
NOAEL of the study.
Taking into account the NOAEL of 750 mg/kg bw per day and by applying an uncertainty factor of
200 (composed of 100 to account for inter- and intraspecies variability, plus a factor of 2 to extrapolate
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from subchronic to chronic exposure (EFSA Scientiﬁc Committee, 2012)), the Panel considers an intake
level of 3.75 mg/kg bw per day as safe.
This level corresponds to 163 mg/day for adolescents from 12 to 14 years of age (mean bw of
43.4 kg), 230 mg/day for adolescents above 14 years of age (mean bw of 61.3 kg) and 263 mg/day
for adults (default bw of 70 kg) (EFSA Scientiﬁc Committee, 2012).
The Panel notes that iodine intake from the NF may be of concern for people at risk of thyroid
disease.
The Panel also notes that intake of other food supplements containing iodine in addition to the NF
might lead to iodine intakes above the UL.
5. Conclusions
The Panel concludes that the NF, Ecklonia cava phlorotannins, is safe for the use in food
supplements at a maximum intake level of 163 mg/day for adolescents from 12 to 14 years of age,
230 mg/day for adolescents above 14 years of age and 263 mg/day for adults.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of Ecklonia cava phlorotannins. Ref. Ares(2016)
3833320, dated 22 July 2016.
2) On 4 August 2016, EFSA received the following documentation: dossier ‘Conf. SeaPolynol
29.04.15’, submitted by Botamedi Inc., Korea; initial assessment report (‘SeaPolynol Initial
Assessment 2182192’) carried out by the Food Safety Authority of Ireland; Member States’
comments and objections; response by the applicant to the initial assessment report and the
Member States’ comments and objections.
3) On 16 September 2016, EFSA sent a request to the applicant to provide missing information
to accompany the application.
4) On 23 September 2016, EFSA received the missing information as submitted by the
applicant. After checking the content of the full dossier, including the newly submitted
information, EFSA considered the application valid as of 29 September 2016.
5) On 2 March 2017, EFSA sent a request to the applicant to provide additional information to
accompany the application.
6) Additional data were provided by the applicant on 28 April 2017.
7) On 8 June 2017, EFSA sent a request to the applicant to provide additional information to
accompany the application.
8) Additional data were provided by the applicant on 6 July 2017.
9) During its meeting on 20 September 2017, the NDA Panel, having evaluated the data,
adopted a scientiﬁc opinion on the safety of Ecklonia cava phlorotannins as a novel food
pursuant to Regulation (EC) No 258/97.
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Abbreviations
ADME absorption, distribution, metabolism and excretion
ALT alanine transaminase
ANOVA analysis of variance (ANOVA)
AST aspartate transaminase
AUC area under the curve
BGLB brilliant green lactose bile
BUN blood urea nitrogen
bw body weight
CHL Chinese hamster lung
DPPH 2,2-diphenyl-1-picrylhydrazyl
dw dry weight
GLP good laboratory practice
GMP good manufacturing practice
GOT glutamic oxaloacetic transaminase
GPT glutamic pyruvic transaminase
1H-NMR proton nuclear magnetic resonance
HACCP Hazard Analysis and Critical Control Points
HPLC high-performance liquid chromatography
hs-CRP high-sensitive C-reactive protein
IC50 inhibition concentration 50%
ICP-MS inductively coupled plasma mass spectrometry
i.p. intraperitoneal
i.v. intravenous
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LDL low-density lipoprotein
LOAEL lowest-observed-adverse-effect-level
LOD limit of detection
MNPCE micronucleated polychromatic erythrocytes
MS Member State
NCE normochromatic erythrocytes
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
NOAEL no-observed-adverse-effect-level
OECD Organisation for Economic Co-operation and Development
p.o. per os
PCE polychromatic erythrocytes
PFF-A phlorofucofuroeckol-A
RH relative humidity
UL upper level
WBC white blood cell
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